Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Steve Patton Named Senior Vice President of Simplified Issue Solutions for AmeriLife Health

AmeriLife

AmeriLife Group, LLC (“AmeriLife”), a national leader in developing, marketing, and distributing life and health insurance, annuities, and retirement planning solutions, announced today that longtime insurance industry veteran Steve Patton has been named Senior Vice President of Simplified Issue Solutions for AmeriLife’s Health Distribution organization. Reporting to AmeriLife’s Chief Distribution Officer for Health Scotty Elliott, Patton will play a pivotal role in shaping and executing AmeriLife Health Distribution’s simplified issue product strategy and roadmap for its Medicare Supplement insurance, final expense life insurance, and health specialty offerings. In this role, Patton will also serve as both a product expert and key liaison with AmeriLife’s carrier partners to help maximize and expand our partnerships and drive increasing value across AmeriLife’s Health Distribution network. “Our decision to appoint Steve underscores our commitment to leveraging top talent in the industry to drive innovation and excellence in our offerings,” said Elliott. “With Steve at the helm, AmeriLife is poised to strengthen its position as a leading distributor of solutions that deliver on our promise of empowering beneficiaries’ holistic wellbeing while continuing to fuel our business’s continued growth.” “I have been blessed to be part of this rewarding industry for more than three decades and am incredibly excited to become part of an extraordinary organization such as AmeriLife,” added Patton. “Abraham Lincoln once said, ‘If opportunity doesn’t knock, build a door,’ and that’s what is truly exciting about the team at AmeriLife: they are building doors to a brighter, more successful future. I’m proud to now be a part of those efforts.” Patton brings a depth of knowledge and expertise to AmeriLife. Prior to joining the company, he served in various key roles, displaying a proven track record of strategic leadership, revenue generation, training, and innovation. For the past 18 years, Patton worked in increasingly senior leadership roles for Aetna’s Supplemental Insurance Division, most recently as its Executive Director and Head of Sales in which he was responsible for all senior product sales. In this role, he also oversaw product and market development, reinsurance, direct-to-consumer sales, and channel development, all while leading a team of 30 insurance professionals across the United States. Patton began his career as a licensed sales agent at Liberty National Life Insurance Company in Lawrenceburg, Tennessee. Patton resides just outside of Nashville with his wife, Tonya, of 32 years. Together, they are deeply involved in their local community, church, and family life, enjoying the outdoors and time spent with their three children. ### About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as an industry leader in developing, marketing and distributing life and health insurance, annuities, and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a national distribution network of over 300,000 agents and financial professionals and more than 160 marketing organizations and insurance agencies. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado +1 321-297-1112 media@amerilife.com Partnership Inquiries Alex Hyer corporatedevelopment@amerilife.com Company Website https://amerilife.com/

November 11, 2024 09:00 AM Eastern Standard Time

Image

Positioned for Growth: Impact BioMedical Inc.'s (NYSEAmerican: IBO) Push into Cancer and Immune Health

IBO

The demand for innovative treatments in oncology and advanced healthcare solutions has never been higher. With cancer still a leading cause of death worldwide, breakthroughs in therapeutic technology are essential. As global investment pours into biotech, driven by an aging population and an increased focus on chronic disease management, companies pursuing novel cancer therapies and immune health solutions are positioned to make a significant impact. In this environment, firms with versatile, patent-backed technologies are set to play an influential role in the future of healthcare. Impact BioMedical Inc. (NYSEAmerican: IBO) has gained momentum with its recent innovations, major partnerships, and expanding intellectual property in healthcare solutions. Focused on biopharmaceuticals and consumer wellness, the company develops proprietary technologies that address unmet needs across oncology, neurology, immunology, and consumer health. With its recent IPO and a seasoned leadership team in place, Impact BioMedical is poised to accelerate its growth and reach in the healthcare market. Successful IPO and Investor Confidence Impact BioMedical’s initial public offering, completed in September 2024, marks a major milestone, providing new resources to push its mission forward. The IPO received strong investor participation, with over 30% of the offering purchased by existing stakeholders—a clear sign of investor confidence in the company’s potential. CEO Frank D. Heuszel noted, “The significant participation of our investors underscores their confidence in our mission and the innovative healthcare solutions we are developing.” This support bolsters Impact BioMedical’s ability to advance its technology platforms and pursue new licensing opportunities. Linebacker Technology Receives Canadian Patent A significant achievement for Impact BioMedical came with the issuance of a Canadian patent for its Linebacker technology. This patent, titled "Electrophilically Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders," covers enhanced phenolic compounds tailored to target inflammatory processes. The Canadian patent highlights Impact BioMedical’s ongoing commitment to tackling inflammatory diseases, a market valued at approximately $7 billion in Canada alone in 2022. Heuszel emphasized the commercial potential of this breakthrough, stating, “This patent issuance strengthens our growing IP portfolio and underscores the innovative nature and commercial and therapeutic potential of our Linebacker technology.” Linebacker compounds target inflammation by regulating key pathways involved in inflammatory responses, presenting an alternative to traditional anti-inflammatory drugs. With potential applications in treating arthritis, asthma, and inflammatory bowel disease, Linebacker could make an impact across multiple therapeutic areas. Beyond inflammation, these compounds have shown promise in oncology and neurology, positioning Linebacker as a versatile platform. The Canadian patent protects these innovations until 2037, adding long-term value to Impact BioMedical’s portfolio. Leadership Team: Vision and Expertise Driving Innovation Following its IPO, IBO introduced its executive team, with Frank D. Heuszel leading as CEO. A finance veteran with extensive experience in commercial banking, Heuszel has been instrumental in steering the company through its IPO and positioning it for growth. He is joined by COO Mark Suseck, an experienced leader in healthcare operations, and CFO Todd Macko, a specialist in fiscal management and corporate strategy. Together, the team brings a wealth of expertise to guide Impact BioMedical into its next phase. Jason Grady, the Director and Interim CEO of DSS Inc., expressed confidence in the leadership, stating, “With their expertise and commitment, we are confident in our ability to advance our mission and deliver impactful healthcare solutions.” This team’s combined experience strengthens the company’s ability to execute its vision for the healthcare market. Beyond Linebacker: Innovative Platforms in Consumer Health Expanding its reach beyond biopharmaceuticals, IBO has developed its 3F technology platform, which recently received a U.S. patent for its insect-repelling composition. The 3F platform uses plant-derived compounds to repel insects by interfering with their olfactory receptors, potentially preventing insect-borne diseases like malaria and dengue fever. Unlike conventional products, 3F offers a natural alternative for repelling insects, with applications in sprays, lotions, and shampoos. Heuszel emphasized the market potential for 3F, commenting, “This is another demonstration of success with our business model delivering new unique proprietary technology with the potential to address unmet needs in human healthcare.” This patent, alongside the existing Linebacker IP, expands Impact BioMedical’s portfolio and opens doors for partnerships in consumer health. Partnerships and Future Directions Impact BioMedical is actively pursuing collaborations to bring its technologies to market, including global partnerships with companies like ProPhase Labs for the commercialization of Linebacker compounds. The Linebacker platform, derived from modified polyphenols such as myricetin, holds potential for multiple therapeutic areas, including oncology, inflammatory disorders, and neurology. Early studies suggest its promise as a co-therapy for cancers, including lung and colon cancer, which are among the leading causes of cancer deaths worldwide. By focusing on scientific advancements and building partnerships, Impact BioMedical positions itself as a forward-thinking player in healthcare. This approach aims to leverage both its research and market reach, ensuring that its technologies make a meaningful impact. Conclusion Impact BioMedical Inc.’s (NYSEAmerican: IBO) blend of innovative technologies, strong leadership, and strategic partnerships sets it apart as a versatile player in the healthcare industry. With a successful IPO, a growing patent portfolio, and applications in both therapeutic and consumer health, the company is well-prepared to make significant strides. Through scientific exploration and dedicated collaborations, IBO could be on track to become a transformative force in human healthcare. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Cambridge Consulting to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

November 11, 2024 07:30 AM Eastern Standard Time

SBC Medical Group (Nasdaq: SBC) CEO: "If We Become No. 1 In Asia, I Believe We Will Become No. 1 In The World"

Benzinga

By Gerelyn Terzo, Benzinga In what social media has declared the “undetectable era” of cosmetic surgery, beauty treatments have never been so appealing. As celebrities such as Christina Aguilera remain transparent about their cosmetic treatments while continuing to turn back the clock on their natural appearance, some experts say any stigma that was once associated with plastic surgery has disappeared. One leader from Asia now making its mark in the industry globally is SBC Medical Group Holdings (NASDAQ: SBC), a Tokyo-based medical company providing franchise services to aesthetic medical clinics and improving the lives of people around the world. In a recently aired webcast, SBC Medical CEO Yoshiyuki Aikawa shared his vision for the future of his growing company while also highlighting investment opportunities now that the stock is trading on the Nasdaq. He also explained that while the company has come so far, there is still more work to be done. Wall Street also seems to have paid attention. In a report released on Oct. 23, Zacks Small-Cap Research placed a $15.40 price target on SBC shares, suggesting the stock has room to almost double in price from its price of $7.23 at the time of the report’s publication. Zacks analyst M. Marin shared her insight on SBC’s franchise model as the company continues to expand its global footprint both organically and through M&A. Investors who are inclined to share in this bullish outlook can keep track of the company’s latest developments here. SBC Medical’s Growth Strategy While SBC Medical only recently became a publicly traded company, it’s been around for over two decades, getting its start as Shonan Beauty Clinic (SBC) in Japan’s Fujisawa city. Fast-forward, and SBC has evolved into a medical provider powerhouse, boasting the biggest network of franchised clinics in Japan and leading the country’s aesthetic medical industry as the Asia population boom continues to unfold. SBC Medical reports that it oversees 220 clinics, including Shoan Beauty clinics, and is growing, reaching close to 4 million customers each year – 70% of whom are repeat patients. Additionally, SBC Medical is in the early stages of international expansion, with clinics located in Los Angeles, CA. and Ho Chi Minh City, Vietnam. With its sights set on further expansion into adjacent fields, including B2B partnerships, SBC Medical, in many ways, is just getting started. “If we become No. 1 in Asia, I believe we will become No. 1 in the world,” said Mr. Aikawa. Chief among the services SBC Medical provides to aesthetic clinics are marketing services, but SBC also supports them in other ways such as recruitment, training, evaluations, medical equipment and expertise. Mr. Aikawa expects these facilities will serve as a springboard to debut additional clinics in these jurisdictions. SBC Medical’s management team represents nearly 25 years of experience in this industry, setting itself apart from the pack with features like a fully digitized integrated system and simplifying things for medical professionals. Its approach seems to be working, as SBC Medical reports that it holds the largest piece of the market share pie in Japan’s medical aesthetic sector, controlling close to one-third of the nation’s growing aesthetic medical segment and further solidifying its leadership position as a franchisor. SBC Medical’s Balance Sheet Mr. Aikawa, who has long been impressed by the effectiveness of aesthetic medicine, pointed to SBC Medical’s solid fundamentals on the balance sheet – the company is generating rising revenue that reached $194 million as of FY2023, coupled with an attractive profit margin. Its diversified portfolio also extends to other self-pay medical treatment areas such as fertility, orthopedic, regenerative medicine and laser eyecare, all of which appeal to many investors. Here’s a snapshot of the company’s financial strength: Revenue YoY Grow: A five-year compound annual growth rate (CAGR) of 24% Gross Profit Margin: 71%-plus Operating Profit Margin: 26%-plus Mr. Aikawa – a visionary whose passion for this business has proven unwavering – has made it his mission for SBC Medical to win. He prioritizes cash on the balance sheet that can be used for growth activities such as M&A. This stable balance sheet would also provide assurance for the sensitive needs of the medical practices that SBC supports. He also has strong hopes for the company’s convenient, trustworthy and efficient online clinical services, including services like AI med provided by the group company, the performance of which has been growing annually. Japan’s Aesthetic Medical Market Growth Potential Japan is a major focus area for SBC Medical, considering only 10% of the country’s population currently seeks aesthetic medical treatments, a low base with enormous potential. Mr. Aikawa expects that segment to at least double to 20% to be closer in line with South Korea’s population turning to cosmetic surgery, owing in part to the advertising campaigns of the Shonan Beauty Clinic. Market penetration among Japan’s core customer group – women up to their 30s – is growing. However, the sweet spot for SBC Medical here is both middle-aged male and female markets, as SBC Medical pursues affordable price points that will make monthly clinic visits possible. “I feel like we are only halfway through achieving that goal, so we should work even harder,” said Mr. Aikawa, pointing out that the number of customers aged 40 is increasing. As SBC Medical continues to expand its clinical base and improve the lives of people around the world, interested investors have an opportunity to participate in its growth story. Zacks’ analyst research suggests SBC Medical has the wind at its back, particularly owing to an increasingly popular aesthetics medicine market in Japan. Investors can learn more about SBC Medical’s stock and fundamentals here. Featured photo by Alexas_Fotos on Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 05, 2024 08:30 AM Eastern Standard Time

Image

News Release

Building Momentum: Zynex Inc.’s (NASDAQ: ZYXI) Steady Rise in the Pain Management Market

ZYXI

Demand for pain management devices is climbing worldwide, fueled by several major trends. As chronic disease rates soar, the need for effective, drug-free pain solutions has grown more pressing. At the same time, advancements in medical tech have opened doors to safer, non-invasive pain relief options, making them more widely adopted by healthcare providers. Rising numbers of surgeries have also created a strong demand for post-operative pain control, while the pain monitoring market continues to surge. With these combined factors, the global pain management device market is expected to reach $5.68 billion by 2032, expanding at a steady 9% CAGR. In this dynamic and fast-evolving field, Zynex Inc. (NASDAQ: ZYXI) stands out as a key player, bringing new solutions to the growing pain management market. A Closer Look at a Leading Innovator in Pain Management Founded in 1996, Zynex Inc. has carved out a unique space in the medical technology industry, specializing in non-invasive medical devices designed for pain management and rehabilitation. With a mission to improve the lives of patients with chronic pain and other debilitating conditions, Zynex consistently develops innovative solutions that support pain management without relying on medications. The recent FDA approval of its latest device, the TensWave, and strong financial performance through Q3 2024 highlight Zynex’s upward trajectory in a growing market. Expanding Product Line with FDA-Cleared TensWave Device Zynex's newest offering, the TensWave device, received FDA clearance in September 2024. This device is a non-invasive pain relief option that uses TENS (Transcutaneous Electrical Nerve Stimulation) technology, a proven method to alleviate pain without medication. According to CEO Thomas Sandgaard, TensWave was developed to meet the demand for a high-quality TENS device that fits insurance reimbursement criteria. "We recognized a gap in the market," Sandgaard said, "and TensWave is our answer to that demand. It complements our flagship device, the NexWave, by giving patients a safe, effective, and drug-free alternative for pain relief." The TensWave device is designed to work in tandem with Zynex’s other products, specifically the NexWave, which offers multiple electrotherapy modalities. While NexWave remains Zynex’s top-tier product, TensWave offers a more targeted solution for patients covered under insurance plans that only reimburse TENS-based treatments. By diversifying its product lineup, Zynex positions itself to cater to a broader range of insurance plans, potentially reaching more patients who need accessible and effective pain management tools. Strong Financial Performance and Business Growth Zynex’s Q3 2024 financial results showcase the company’s resilience and growth momentum. During the quarter, orders in the Pain Management division saw a 13% increase compared to the same period in 2023, while revenue per sales representative jumped by 25%, reaching approximately $530,000. Overall, Zynex reported net revenue of $50 million, a slight increase from the previous year, and net income of $2.4 million, equating to an EPS of $0.07. Cash flow from operations was robust at $7.1 million, and the company’s working capital stood at $58.5 million as of September 30, 2024. In February 2022, an article from Seeking Alpha suggested that Zynex might face a 50% drop in EBITDA due to contract changes with UnitedHealthcare. However, rather than the anticipated loss, Zynex managed to maintain and even grow its partnership with UnitedHealthcare. Over the past three years, Zynex has consistently added new patients with UnitedHealthcare, backed by a renewed agreement with the insurer. Notably, Zynex has recorded steady revenue growth, with year-over-year increases of 21%, 17%, and 9% since 2022, effectively countering these earlier predictions and showcasing Zynex’s operational strength. Looking ahead to Q4, Zynex has set a revenue target of $53.6 million with an estimated EPS of $0.09. For the full year of 2024, the company expects to achieve net revenue of at least $200 million, representing a 9% growth from the prior year and an EPS of $0.20. These projections suggest that Zynex is on track to sustain its current pace of expansion. Strategic Focus on Innovation and Market Adaptability One of Zynex’s core strengths lies in its ongoing commitment to research and development, aiming to diversify its product portfolio to address unmet needs in pain management. Sandgaard has emphasized that Zynex’s long-term goals include not just incremental growth in its pain management division but also the expansion of its orthopedic products, ensuring that the company has a well-rounded suite of medical devices. In the words of Sandgaard, “We are working to expedite the onboarding of new sales reps while maintaining a high standard for productivity. Our focus on FDA approvals of next-generation devices and new therapy products delivered FDA clearance of our new TensWave device during the quarter.” Alongside pain management, Zynex is making strides in non-invasive monitoring systems for hospital use, indicating that the company is serious about diversifying beyond its core offerings. This multi-pronged approach gives Zynex the flexibility to adjust to changing market demands while further establishing its reputation as a provider of comprehensive, non-invasive healthcare solutions. Future Growth Potential With the FDA approval of the TensWave device, Zynex has reinforced its presence in the pain management market, where demand for non-opioid treatment options is on the rise. The device could become a significant revenue driver, particularly as the opioid crisis has heightened interest in alternative pain management therapies. TENS therapy, a proven method for reducing both chronic and acute pain, positions Zynex favorably among patients and healthcare providers looking for safe, effective treatments. Zynex’s current product line also includes devices for cold and hot therapy, cervical traction, braces, and compression solutions, allowing it to cater to a broad array of patient needs. As the company anticipates a return to its typical growth rate of approximately 20% in the pain management division in 2025, the new products and strong sales infrastructure could enable it to scale more effectively. Conclusion In 2024, Zynex Inc. (NASDAQ: ZYXI) has shown resilience by expanding its product portfolio and maintaining steady growth. The FDA clearance of the TensWave device further strengthens its position in the non-invasive pain management field, supporting its mission to deliver effective, drug-free pain solutions. With solid revenue growth and strong partnerships, ZYXI is set to build on its progress, providing lasting value for patients and shareholders alike. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Awareness Consulting to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

November 05, 2024 07:00 AM Eastern Standard Time

Market Alert: New Report Highlights Steakholder Foods Major Shift to Commercialization & Revenue Generation

Global Markets News

A new report by PESG Research highlights Steakholder Foods’ (NASDAQ: STKH) transformative journey from research and development to commercialization in the alternative protein and 3D food printing sectors. The report highlights how 2024 marked a pivotal year for the company, with strategic partnerships fueling revenue generation and positioning Steakholder Foods for potential growth in a booming market. Strategic Partnerships Lay Foundation for Revenue Growth Steakholder Foods secured multiple strategic agreements in 2024 that validate its proprietary technology and solidify its commercial potential. Key partnerships include a commercial memorandum of understanding with Wyler Farm, which involves the purchase of Steakholder Foods’ MX200 meat printer and SH™-Beef premix blends. This agreement also encompasses royalties and raw materials supply, enabling large-scale production of alternative proteins. Additional partnerships with the Industrial Technology Research Institute (ITRI) in Taiwan and regional collaborations in the Gulf Cooperation Council (GCC) highlight the company’s international reach. The GCC partnership, aimed at supporting local food security initiatives, involves constructing a pilot facility for hybrid-cultivated fish production and showcases Steakholder Foods’ scalability in new markets. These agreements are seen as significant steps toward establishing long-term, recurring revenue streams. Initial Purchase Orders Signal Commercial Viability According to the company, initial purchase orders from key partners such as Bondor Foods and Wyler Farm have initiated revenue streams, providing critical proof of concept for Steakholder Foods’ business model. In September 2024, Bondor Foods placed its first order for plant-based premixes for white fish and salmon patties, followed by Wyler Farm’s order for SH™-Beef premix for a new line of plant-based meat products. These initial revenues underscore the company’s successful transition from R&D to commercialization. Moreover, in a bid to attract new clients and partners, Steakholder Foods inaugurated a state-of-the-art Demonstration Center in Israel. The facility showcases live demonstrations of its MX200 and HD144 3D printers, highlighting their capabilities in real-time production of plant-based meat and seafood alternatives. This hands-on experience allows potential partners to witness the full production process, reinforcing the quality and versatility of Steakholder Foods’ offerings. Positioned for Potential Growth in Expanding Markets The PESG report places Steakholder Foods within the context of a rapidly expanding alternative protein market, projected to grow from $76.3 billion in 2023 to $423 billion by 2033. This growth is driven by consumer interest in sustainable and health-conscious food options. Additionally, the 3D food printing market is expected to surge, with estimates forecasting growth from USD 34.7 million in 2019 to USD 1,015.4 million by 2027, driven by advances in technology and consumer demand for innovative food solutions. The report highlights how Steakholder Foods’ advancements potentially align with these industry trends, positioning the company as a potential leader in sustainable food production. Its proprietary 3D printing technology and strategic partnerships are poised to capture a share of this growing demand, particularly as cost management initiatives and recurring revenues take effect. Outlook and Future Prospects With strategic partnerships maturing and a demonstration center enhancing its market presence, Steakholder Foods appears poised for potential revenue growth in the coming years. The company has noted that it is in advanced discussions for a high-impact international agreement expected to close by early 2025. This move could further bolster Steakholder Foods’ position as a leader in the alternative protein sector, which continues to gain momentum amid shifting consumer preferences and sustainability goals. Read the Full PESG Report: https://finance.yahoo.com/news/pesg-research-report-steakholder-foods-134500909.html *Please refer to the report’s full disclaimers and disclosures. This news alert may include speculative forward looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Companies in emerging industries are volatile and risky and readers are advised to seek out preffesional advice in the relevent feilds from licensed profesionals. *** This news alert is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. Global Markets News Network is a commercial digital brand compensated by the issuer (STKH) to provide coverage, sharing and syndication of news related to it and is thus subject to conflicts of interest. [ https://justpaste.it/bdh8v/pdf ]. Contact Details News Coverage globalmarkets.media@gmail.com

November 04, 2024 10:40 AM Eastern Standard Time

PathAI Launches PathExplore™ Fibrosis: An AI-Powered Pathology Breakthrough in Fibrosis, Collagen, and Fiber Quantification Directly from Whole Slide Images

PathAI

PathAI, a leader in AI-powered pathology solutions, is proud to introduce PathExplore™ Fibrosis 1 on our AISight® Translational Research platform, a one-of-a-kind AI tool designed to revolutionize fibrosis, collagen, and fiber quantification directly from whole-slide images (WSIs) of hematoxylin and eosin (H&E)-stained tissue. PathExplore™ Fibrosis offers an unprecedented ability to analyze morphology and spatial organization of fibrosis in the tumor microenvironment (TME) directly from routine pathology images at scale, providing new insights into tumor biology and therapeutic response. Fibrosis and collagen fibers are emerging as crucial biomarkers and drug targets due to their potential roles in cancer progression, metastasis, and immune response. Leveraging advanced machine learning techniques, PathExplore™ Fibrosis offers scalable, rapid analysis, making it a transformative tool in oncology translational research. PathAI’s solution facilitates this analysis directly from routine H&E pathology images from standard imaging platforms, democratizing access to key insights into tumor biology and therapeutic responses without the need of custom microscopy. "What began as internal research by our scientific team has evolved into a powerful tool for cancer researchers, enabling them to explore previously inaccessible aspects of tumor morphology," said Ben Glass, VP of Product and Translational Research at PathAI. "Fibrosis is increasingly recognized as a potentially important biomarker in cancer research. By making it possible to study this directly from routine H&E images, we’re providing researchers with the means to scale their understanding of disease biology, evaluate drug efficacy, and drive the development of new fibrosis-related therapies." “By combining the cell and tissue features provided by PathExplore™ 2 with collagen and fibrosis measurements from PathExplore™ Fibrosis, researchers now have access to an unprecedented multidimensional view of the TME,” said Eric Walk, M.D., FCAP, chief medical officer at PathAI. “From a single image, researchers can ask and answer new questions about the organization and morphology of fibrosis in the TME and how this inhibits or promotes cancer progression.” PathAI will be presenting novel findings utilizing PathExplore™ Fibrosis and the underlying technology at the upcoming Society of Immunotherapy of Cancer conference (SITC 2024) on November 6-11, 2024, in Houston, Texas. Be one of the first to access PathExplore™ Fibrosis by reaching out to us at bd@pathai.com or access our self-serve demo of PathExplore™ Fibrosis for hands-on experience here. SITC 2024 Abstracts #1378: Stromal collagen features from H&E-stained whole slide images are associated with lymphocyte infiltration and survival following checkpoint inhibition in patients with non-small cell lung cancer - in collaboration with Incendia Therapeutics #88: Machine learning-based collagen fiber quantification enables analysis of the pancreatic cancer tumor microenvironment directly from hematoxylin and eosin-stained whole slide images Footnotes 1: PathExplore™ Fibrosis is for research use only. Not for use in diagnostic procedures. 2: PathExplore™ is for research use only. Not for use in diagnostic procedures. About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples, with the potential to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI is headquartered in Boston, MA. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

November 04, 2024 10:00 AM Eastern Standard Time

ETFs: A Streamlined Approach to Sector-Specific Investment

Select Sector SPDR

In the dynamic world of financial markets, the Select Sector SPDR ETFs offer a practical method for investors seeking sector-specific investments. By segmenting the S&P 500 into defined sectors, these ETFs present both individual and institutional investors with an opportunity to build more targeted and strategic investment portfolios. Select Sector SPDR ETFs are designed to cater to various segments of the economy, allowing investors to concentrate their investments based on specific economic sectors, aligned with their investment goals, risk tolerance, and market perspectives. Overview of the available Select Sector SPDR ETFs Communication Services Select Sector SPDR Fund (XLC) is centered around telecommunications and media companies. Consumer Discretionary Select Sector SPDR Fund (XLY) is comprised of companies involved in non-essential goods and services focused on luxury items, automobiles, and hotels. Consumer Staples Select Sector SPDR Fund (XLP) is primarily essential consumer goods and services like beverages, clothing, and personal products. Energy Select Sector SPDR Fund (XLE) is focused on the energy sector which includes oil and natural gas industries. Financials Select Sector SPDR Fund (XLF) includes banking, capital markets, and insurance industries. Health Care Select Sector SPDR Fund (XLV) is dedicated to pharmaceuticals, healthcare equipment, and biotechnology. Industrials Select Sector SPDR Fund (XLI) encompasses manufacturing, construction, and aerospace companies. Materials Select Sector SPDR Fund (XLB) focuses on mining, construction materials, and packaging sectors. Real Estate Select Sector SPDR Fund (XLRE) looks into commercial real estate services and Real Estate Investment Trusts (REITs), excluding Mortgage REITs. Technology Select Sector SPDR Fund (XLK) is focused on the information technology, semiconductor, and electronics industries. Utilities Select Sector SPDR Fund (XLU) centers around electricity and natural gas companies. The Select Sector SPDR ETFs provide an uncomplicated and transparent way to navigate sector-specific investments, allowing investors to adjust their strategies in response to ever-changing market dynamics. This sector-focused approach can provide detailed analysis and strategic portfolio management, offering a valuable tool for investors to fine-tune their investment allocations. As the ETF landscape continues to evolve, the Select Sector SPDR provides a mechanism for investors aiming to fine tune their investment strategies through focused sector allocations. This structured investment avenue supports the development of robust and adaptive portfolios, tailored to meet diverse investor needs and market conditions. DISCLAIMER: This is a work of research and should not be taken as investment or financial advice. Therefore, Select Sector SPDRs or the publisher is not liable for any decision made based on the publication. About the Company: Select Sector SPDR ETFs offer flexibility and customization opportunities. Many investors have similar outlooks, but no two are exactly alike. Select Sector SPDR ETFs let investors select the sectors that best meet their investment goals. DISCLOSURES The S&P 500 Index is an unmanaged index of 500 common stocks that is generally considered representative of the U.S. stock market. The index is heavily weighted toward stocks with large market capitalizations and represents approximately two-thirds of the total market value of all domestic common stocks. The S&P 500 Index figures do not reflect any fees, expenses or taxes. An investor should consider investment objectives, risks, fees and expenses before investing. One may not invest directly in an index. Transparent ETFs provide daily disclosure of portfolio holdings and weightings All ETFs are subject to risk, including loss of principal. Sector ETF products are also subject to sector risk and nondiversification risk, which generally will result in greater price fluctuations than the overall market. Diversification does not eliminate risk. An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain a prospectus, which contains this and other information, call 1-866-SECTOR-ETF (732-8673) or visit www.sectorspdrs.com. Read the prospectus carefully before investing. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is distributor for the Select Sector SPDR Trust. Media Contact: Company: Select Sector SPDRs Contact: Dan Dolan* Address: 1290 Broadway, Suite 1000, Denver, CO 80203 Country: United States Email: dan.dolan@sectorspdrs.com Website: https://www.sectorspdrs.com/ *Dan Dolan is a Registered Representative of ALPS Portfolio Solutions Distributor, Inc. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is the distributor for the Select Sector SPDR Trust. SEL007907 EXP 12/31/24 Contact Details Dan Dolan +1 203-935-8103 dan.dolan@sectorspdrs.com Company Website https://www.sectorspdrs.com/

November 01, 2024 05:00 AM Eastern Daylight Time

VIZIA Diagnostics Selects PathAI and the AISight Image Management System to Support the Transition to Digital and AI-Powered Pathology

PathAI

PathAI, a leader in digital and AI-powered pathology solutions, and VIZIA Diagnostics, a GI- specialized pathology laboratory based in Alpharetta, Georgia, have announced that VIZIA has adopted PathAI’s AISight Ⓡ1 Image Management System (IMS) and AI technology to advance the precision and operational efficiency of its pathology services. In today’s rapidly evolving pathology landscape, independent labs face increasing pressure to provide timely and accurate assessments. To meet these demands, VIZIA Diagnostics conducted a thorough evaluation of digital pathology solutions and selected PathAI’s AISight Image Management System as the ideal platform. AISight’s robust workflow optimization, advanced case management, and broad applicability across various use cases were key factors in the decision. By integrating AISight with algorithm products, VIZIA Diagnostics aims to improve turnaround times for their clients and deliver even higher-quality pathology services. "AISight offers more than just efficiency; it empowers us to lead in the evolving field of gastrointestinal pathology," said Gregg Costantino, CEO of VIZIA Diagnostics. "By streamlining our workflows and enhancing accuracy, we're able to deliver faster, more precise results for our clients. This collaboration aligns with our commitment to being a flexible and quality-focused partner, providing exceptional service and care in the GI space, and positioning us at the forefront of digital and AI pathology." "The transformative potential of AI and Digital Pathology, coupled with the growing need for business-critical solutions our pathologists and GI providers require, was at the forefront of our decision to adopt this system," added Ed Cochrane, commercial director of VIZIA Diagnostics. “PathAI’s platform provides us unmatched agility and responsiveness for the dynamic landscape of anatomic pathology and our diverse customer base”. "The selection of PathAI by VIZIA Diagnostics reflects our shared commitment to improving patient outcomes through innovative, digital, and AI-powered pathology solutions," said Andy Beck, MD, PhD, co-founder and CEO of PathAI. "By adopting these technologies, VIZIA Diagnostics is well-positioned to meet the growing demand for more efficient, high-quality pathology operations. We are excited to support them as they embark on their digital journey to transform their pathology services." AISight is a cloud-native, intelligent enterprise workflow solution trusted by pathologists worldwide. As a centralized platform for case management, workload balancing, and image management, AISight seamlessly integrates best-in-class artificial intelligence tools from PathAI and third-party partners. This comprehensive approach will enable VIZIA Diagnostics to address a broad spectrum of histopathology use cases efficiently and consistently. Footnote 1. AISight is for Research Use Only. Not for use in diagnostic procedures. About PathAI PathAI is a leading provider of integrated AI and digital pathology solutions dedicated to transforming workflow and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. For more information, please visit www.pathai.com. About VIZIA Diagnostics VIZIA Diagnostics is an established leader in gastrointestinal pathology, dedicated to advancing diagnostic services through enhanced processes and exceptional patient care. As a vital partner in healthcare, VIZIA leverages advanced, modern technology and the expertise of its dedicated team to deliver accurate, timely, and reliable results. Focused on setting new industry standards, VIZIA's experts ensure that these advanced solutions elevate the quality of GI diagnostics and improve patient outcomes. For more information on VIZIA Diagnostics, please visit www.viziadx.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

October 31, 2024 10:00 AM Eastern Daylight Time

Intus Care to Host Virtual Roundtable on “PACE & The Future of Healthcare Data Interoperability”

Intus Care

Intus Care, a technology leader in the PACE market, will host a virtual conversation on “PACE and the Future of Healthcare Data Interoperability” with prominent guests within healthcare and the PACE (Programs of All-Inclusive Care for the Elderly) community. Intus Care Cofounder and CEO Robbie Felton will moderate a discussion among Shawn Bloom, CEO and president of the National PACE Association (NPA); Dr. David Feinberg, Chairman of Oracle Health (formerly CEO of Cerner); and Stephanie Rock, Vice President of Product at Intus Care. The discussion will center around healthcare system interoperability, the importance of interoperability, and the current interoperability challenges that remain. In particular, the conversation will focus around: What can the PACE community learn from modern interoperability standards by the broader value-based care community? Why does PACE need an interoperable and modular technology strategy as the model expands? The hour virtual roundtable is scheduled for Thursday, November 14 at 1 p.m. ET. Anyone interested in interoperability, healthcare, and PACE is invited to listen to the discussion. Registration is open now. PACE is a “comprehensive, fully integrated, provider-based health plan for the frailest and costliest members of our society – those who require a nursing home level of care,” according to the National PACE Association. The goal, however, is to provide care that allows those enrolled to continue living at home and in their communities. Nationally, 95% of participants continue to live at home. The model is now considered the gold standard for seniors with complex care needs. According to the NPA, there are currently 178 PACE programs serving more than 78,500 participants in 33 states and the District of Columbia. As the U.S. population ages – adults 65 years or older will increase 30%, from 63 million to 82 million, accounting for nearly one-quarter of the U.S. population by 2050 – the need for PACE to expand will only increase. To scale effectively, PACE organizations need technology that meets their needs, including a unified documentation system that integrates and shares data securely and seamlessly. "The future of interoperability in PACE lies in seamless data sharing across care teams, empowering providers to deliver truly coordinated, patient-centered care," said Felton. "While progress has been made, there are still regulatory and technological hurdles for this to be truly realized for PACE organizations, but its realization will unlock unprecedented value and transform how we care for our aging population. I look forward to unpacking this with our esteemed guests for the virtual fireside chat." Registration for the virtual roundtable is open now. A recording will be available following the event for individuals unable to attend live. About Intus Care Intus Care creates technology and services for PACE and value-based care organizations to achieve operational efficiency and better clinical and financial outcomes. Intus Care currently works with over 60 PACE programs across 16 states. Visit our website to learn more at intuscare.com. Contact Details SVM Public Relations +1 401-490-9700 intuscare@svmpr.com Company Website https://www.intuscare.com/

October 31, 2024 10:00 AM Eastern Daylight Time

1 2 3 4 5 ... 308